Skip to search formSkip to main contentSkip to account menu

lenvatinib

Known as: 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide, 4-(3-chloro-4-(N'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide, 4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide 
A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with… 
National Institutes of Health

Related topics

Related topics

13 relations

Broader (4)

Antineoplastic AgentsPhenylurea CompoundsProtein Kinase InhibitorsQuinolines

Narrower (3)

E 7080Lenvimalenvatinib mesylate
E7080NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase InhibitionReceptor Tyrosine Kinase Inhibitors [MoA]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
The SHARP study in 2007 [1] and the Asia Pacific study in 2008 [2] led to the worldwide approval of sorafenib as the standard… 
Review
2017
Review
2017
Which patient with thyroid cancer deserves systemic therapy and when?
Review
2017
Review
2017
Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
2017
2017
Circulating Tumor BRAF Mutation and Personalized Thyroid Cancer Treatment
Circulating tumor DNA (ctDNA) is now being extensively studied as it is a noninvasive “real-time” biomarker that can provide… 
2016
2016
Perspective: What next for treatment?
We need to focus on five main areas to make real progress in the treatment of kidney cancer, says Robert J. Motzer. 
2016
2016
Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis results.
6088Background: Thyroid cancer is classified into differentiated (DTC), medullary (MTC), and anaplastic (ATC) types. Lenvatinib… 
2014
2014
Molecular Pathways Associated with Aggressiveness of Papillary Thyroid Cancer
The most common thyroid malignancy is papillary thyroid cancer (PTC). Mortality rates from PTC mainly depend on its… 
2013
2013
A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: Angiopoietin-2 as a predictive marker for clinical outcomes.
5520 Background: Lenvatinib is an oral receptor tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT, and PDGFRβ. The… 
2012
2012
A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).
5591 Background: Lenvatinib is an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT and PDGFRβ. In phase I… 
2012
2012
Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): Cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers…
5518 Background: Lenvatinib is an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT and PDGFRβ. In a phase II… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)